Tyra gains orphan drug status from FDA for achondroplasia therapy
Tyra Biosciences has received orphan drug designation (ODD) from the US FDA for TYRA-300 to treat achondroplasia, a common form of dwarfism.
Tyra Biosciences has received orphan drug designation (ODD) from the US FDA for TYRA-300 to treat achondroplasia, a common form of dwarfism.
What's Your Reaction?
